0 CHECKOUT

Cognitive Impairment Associated With Schizophrenia (CIAS) - Pipeline Review, H2 2015

  • ID: 3495969
  • October 2015
  • 110 pages
  • Global Markets Direct
1 of 4

FEATURED COMPANIES

  • AbbVie Inc.
  • Astellas Pharma Inc.
  • Eli Lilly and Company
  • H. Lundbeck A/S
  • Iproteos S.L.
  • Neuralstem, Inc.
  • MORE

Cognitive Impairment Associated With Schizophrenia (CIAS) - Pipeline Review, H2 2015

Summary

The report ‘Cognitive Impairment Associated With Schizophrenia (CIAS) - Pipeline Review, H2 2015’, provides an overview of the Cognitive Impairment Associated With Schizophrenia (CIAS)’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Cognitive Impairment Associated With Schizophrenia (CIAS), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Cognitive Impairment Associated With Schizophrenia (CIAS) and special features on late-stage and discontinued projects.

The report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, Company/University websites, SEC filings, investor presentations and featured press READ MORE >

Note: Product cover images may vary from those shown
2 of 4

FEATURED COMPANIES

  • AbbVie Inc.
  • Astellas Pharma Inc.
  • Eli Lilly and Company
  • H. Lundbeck A/S
  • Iproteos S.L.
  • Neuralstem, Inc.
  • MORE

List of Tables

List of Figures

Introduction

REPORT COVERAGE

Cognitive Impairment Associated With Schizophrenia (CIAS) Overview

Therapeutics Development

Pipeline Products for Cognitive Impairment Associated With Schizophrenia (CIAS) - Overview

Pipeline Products for Cognitive Impairment Associated With Schizophrenia (CIAS) - Comparative Analysis

Cognitive Impairment Associated With Schizophrenia (CIAS) - Therapeutics under Development by Companies

Cognitive Impairment Associated With Schizophrenia (CIAS) - Pipeline Products Glance

Late Stage Products

Clinical Stage Products

Early Stage Products

Cognitive Impairment Associated With Schizophrenia (CIAS) - Products under Development by Companies

Cognitive Impairment Associated With Schizophrenia (CIAS) - Companies Involved in Therapeutics Development

AbbVie Inc.

Amarantus Bioscience Holdings, Inc.

Astellas Pharma Inc.

Avineuro Pharmaceuticals, Inc.

Bristol-Myers Squibb Company

Eli Lilly and Company

FORUM Pharmaceuticals Inc.

H. Lundbeck A/S

Intra-Cellular Therapies, Inc.

Iproteos S.L.

Mnemosyne Pharmaceuticals, Inc.

Neuralstem, Inc.

Pfizer Inc.

Saniona AB

Siena Biotech S.p.A.

SK Biopharmaceuticals Co., Ltd.

Sunovion Pharmaceuticals Inc.

Takeda Pharmaceutical Company Limited

Upsher-Smith Laboratories, Inc.

Vanda Pharmaceuticals Inc.

Cognitive Impairment Associated With Schizophrenia (CIAS) - Therapeutics Assessment

Assessment by Monotherapy Products

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Drug Profiles

A-431404 - Drug Profile

Product Description

Mechanism of Action

R&D Progress

AN-761 - Drug Profile

Product Description

Mechanism of Action

R&D Progress

AQW-051 - Drug Profile

Product Description

Mechanism of Action

R&D Progress

ASP-4345 - Drug Profile

Product Description

Mechanism of Action

R&D Progress

ASP-5736 - Drug Profile

Product Description

Mechanism of Action

R&D Progress

AUT-1 - Drug Profile

Product Description

Mechanism of Action

R&D Progress

AUT-6 - Drug Profile

Product Description

Mechanism of Action

R&D Progress

AUT-9 - Drug Profile

Product Description

Mechanism of Action

R&D Progress

AVL-3288 - Drug Profile

Product Description

Mechanism of Action

R&D Progress

AVN-211 - Drug Profile

Product Description

Mechanism of Action

R&D Progress

DSP-3748 - Drug Profile

Product Description

Mechanism of Action

R&D Progress

eltoprazine - Drug Profile

Product Description

Mechanism of Action

R&D Progress

encenicline hydrochloride - Drug Profile

Product Description

Mechanism of Action

R&D Progress

erteberel - Drug Profile

Product Description

Mechanism of Action

R&D Progress

IC-041 - Drug Profile

Product Description

Mechanism of Action

R&D Progress

IPR-001 - Drug Profile

Product Description

Mechanism of Action

R&D Progress

IPR-088 - Drug Profile

Product Description

Mechanism of Action

R&D Progress

IPR-19 - Drug Profile

Product Description

Mechanism of Action

R&D Progress

ITI-214 - Drug Profile

Product Description

Mechanism of Action

R&D Progress

LUAF-64280 - Drug Profile

Product Description

Mechanism of Action

R&D Progress

NSI-189 - Drug Profile

Product Description

Mechanism of Action

R&D Progress

PF-04958242 - Drug Profile

Product Description

Mechanism of Action

R&D Progress

PNU-120596 - Drug Profile

Product Description

Mechanism of Action

R&D Progress

roflumilast - Drug Profile

Product Description

Mechanism of Action

R&D Progress

SEN-15924 - Drug Profile

Product Description

Mechanism of Action

R&D Progress

SKL-15508 - Drug Profile

Product Description

Mechanism of Action

R&D Progress

SKL-A4R - Drug Profile

Product Description

Mechanism of Action

R&D Progress

Small Molecule to Agonize Neuronal Acetylcholine Receptor Subunit Alpha-7 for Central Nervous System - Drug Profile

Product Description

Mechanism of Action

R&D Progress

Small Molecules for Cognitive Impairment Associated with Schizophrenia - Drug Profile

Product Description

Mechanism of Action

R&D Progress

Small Molecules to Agonize Dopamine D1 Receptor for Cognitive Impairment Associated with Schizophrenia - Drug Profile

Product Description

Mechanism of Action

R&D Progress

Small Molecules to Agonize NMDA2B for CIAS - Drug Profile

Product Description

Mechanism of Action

R&D Progress

TAK-058 - Drug Profile

Product Description

Mechanism of Action

R&D Progress

TAK-915 - Drug Profile

Product Description

Mechanism of Action

R&D Progress

Cognitive Impairment Associated With Schizophrenia (CIAS) - Recent Pipeline Updates

Cognitive Impairment Associated With Schizophrenia (CIAS) - Dormant Projects

Cognitive Impairment Associated With Schizophrenia (CIAS) - Discontinued Products

Cognitive Impairment Associated With Schizophrenia (CIAS) - Product Development Milestones

Featured News & Press Releases

Sep 14, 2015: FORUM Pharmaceuticals Updates Encenicline Phase 3 Clinical Trial Programs in Alzheimer’s Disease and Cognitive Impairment in Schizophrenia

Jul 15, 2015: FORUM Pharmaceuticals Announces Publication of Encenicline Phase 2 Clinical Trial Results for Cognitive Impairment in Schizophrenia

Jun 22, 2015: FORUM Pharmaceuticals Receives FDA Fast Track Designation for Lead Compound Encenicline to Treat Cognitive Impairment in Schizophrenia

Jun 11, 2015: FORUM Pharmaceuticals Completes Patient Enrollment in Pivotal Phase 3 Clinical Trial Program of Encenicline for Cognitive Impairment in Schizophrenia

Apr 17, 2013: SK Biopharma Announces FDA's Authorization Of IND For SKL15508 For Treatment Of Cognitive Impairment Associated With Schizophrenia

Feb 19, 2013: Intra-Cellular Therapies Completes Phase I Single Rising Dose Trial Of Selective Phosphodiesterase 1 Inhibitor

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

Number of Products under Development for Cognitive Impairment Associated With Schizophrenia (CIAS), H2 2015

Number of Products under Development for Cognitive Impairment Associated With Schizophrenia (CIAS) - Comparative Analysis, H2 2015

Number of Products under Development by Companies, H2 2015

Comparative Analysis by Late Stage Development, H2 2015

Comparative Analysis by Clinical Stage Development, H2 2015

Comparative Analysis by Early Stage Development, H2 2015

Products under Development by Companies, H2 2015

Products under Development by Companies, H2 2015 (Contd..1)

Cognitive Impairment Associated With Schizophrenia (CIAS) - Pipeline by AbbVie Inc., H2 2015

Cognitive Impairment Associated With Schizophrenia (CIAS) - Pipeline by Amarantus Bioscience Holdings, Inc., H2 2015

Cognitive Impairment Associated With Schizophrenia (CIAS) - Pipeline by Astellas Pharma Inc., H2 2015

Cognitive Impairment Associated With Schizophrenia (CIAS) - Pipeline by Avineuro Pharmaceuticals, Inc., H2 2015

Cognitive Impairment Associated With Schizophrenia (CIAS) - Pipeline by Bristol-Myers Squibb Company, H2 2015

Cognitive Impairment Associated With Schizophrenia (CIAS) - Pipeline by Eli Lilly and Company, H2 2015

Cognitive Impairment Associated With Schizophrenia (CIAS) - Pipeline by FORUM Pharmaceuticals Inc., H2 2015

Cognitive Impairment Associated With Schizophrenia (CIAS) - Pipeline by H. Lundbeck A/S, H2 2015

Cognitive Impairment Associated With Schizophrenia (CIAS) - Pipeline by Intra-Cellular Therapies, Inc., H2 2015

Cognitive Impairment Associated With Schizophrenia (CIAS) - Pipeline by Iproteos S.L., H2 2015

Cognitive Impairment Associated With Schizophrenia (CIAS) - Pipeline by Mnemosyne Pharmaceuticals, Inc., H2 2015

Cognitive Impairment Associated With Schizophrenia (CIAS) - Pipeline by Neuralstem, Inc., H2 2015

Cognitive Impairment Associated With Schizophrenia (CIAS) - Pipeline by Pfizer Inc., H2 2015

Cognitive Impairment Associated With Schizophrenia (CIAS) - Pipeline by Saniona AB, H2 2015

Cognitive Impairment Associated With Schizophrenia (CIAS) - Pipeline by Siena Biotech S.p.A., H2 2015

Cognitive Impairment Associated With Schizophrenia (CIAS) - Pipeline by SK Biopharmaceuticals Co., Ltd., H2 2015

Cognitive Impairment Associated With Schizophrenia (CIAS) - Pipeline by Sunovion Pharmaceuticals Inc., H2 2015

Cognitive Impairment Associated With Schizophrenia (CIAS) - Pipeline by Takeda Pharmaceutical Company Limited, H2 2015

Cognitive Impairment Associated With Schizophrenia (CIAS) - Pipeline by Upsher-Smith Laboratories, Inc., H2 2015

Cognitive Impairment Associated With Schizophrenia (CIAS) - Pipeline by Vanda Pharmaceuticals Inc., H2 2015

Assessment by Monotherapy Products, H2 2015

Number of Products by Stage and Target, H2 2015

Number of Products by Stage and Mechanism of Action, H2 2015

Number of Products by Stage and Route of Administration, H2 2015

Number of Products by Stage and Molecule Type, H2 2015

Cognitive Impairment Associated With Schizophrenia (CIAS) Therapeutics - Recent Pipeline Updates, H2 2015

Cognitive Impairment Associated With Schizophrenia (CIAS) - Dormant Projects, H2 2015

Cognitive Impairment Associated With Schizophrenia (CIAS) - Dormant Projects (Contd..1), H2 2015

Cognitive Impairment Associated With Schizophrenia (CIAS) - Discontinued Products, H2 2015

List of Figures

Number of Products under Development for Cognitive Impairment Associated With Schizophrenia (CIAS), H2 2015

Number of Products under Development for Cognitive Impairment Associated With Schizophrenia (CIAS) - Comparative Analysis, H2 2015

Number of Products under Development by Companies, H2 2015

Comparative Analysis by Clinical Stage Development, H2 2015

Comparative Analysis by Early Stage Products, H2 2015

Assessment by Monotherapy Products, H2 2015

Number of Products by Top 10 Targets, H2 2015

Number of Products by Stage and Top 10 Targets, H2 2015

Number of Products by Top 10 Mechanism of Actions, H2 2015

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2015

Number of Products by Top 10 Routes of Administration, H2 2015

Number of Products by Stage and Top 10 Routes of Administration, H2 2015

Number of Products by Top 10 Molecule Types, H2 2015

Number of Products by Stage and Top 10 Molecule Types, H2 2015

Note: Product cover images may vary from those shown
3 of 4

AbbVie Inc.
Amarantus Bioscience Holdings, Inc.
Astellas Pharma Inc.
Avineuro Pharmaceuticals, Inc.
Bristol-Myers Squibb Company
Eli Lilly and Company
FORUM Pharmaceuticals Inc.
H. Lundbeck A/S
Intra-Cellular Therapies, Inc.
Iproteos S.L.
Mnemosyne Pharmaceuticals, Inc.
Neuralstem, Inc.
Pfizer Inc.
Saniona AB
Siena Biotech S.p.A.
SK Biopharmaceuticals Co., Ltd.
Sunovion Pharmaceuticals Inc.
Takeda Pharmaceutical Company Limited
Upsher-Smith Laboratories, Inc.
Vanda Pharmaceuticals Inc.

Note: Product cover images may vary from those shown
4 of 4
Note: Product cover images may vary from those shown

PLEASE SELECT A FORMAT

  • Quick Help: The report will be emailed to you. The report is sent in PDF format. This is a single user license, allowing one specific user access to the product.

  • Quick Help: The report will be emailed to you. The report is sent in PDF format. This is a site license, allowing all users within a given geographical location of your organisation access to the product.

  • Quick Help: The report will be emailed to you. The report is sent in PDF format. This is an enterprise license, allowing all employees within your organisation access to the product.

HAVE A QUESTION?

If you have a more general question about our products please try our

FAQ SECTION

RELATED PRODUCTS from Cache

Our Clients

  • Amneal Pharmaceuticals LLC.
  • Amgen Inc.
  • LEO Laboratories Ltd.
  • Pfizer Inc.
  • Roche Diagnostics Ltd.
  • Merck & Co., Inc.
  • Sanofi S.A.